Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Московская медицинская академия им. И.М.Сеченова
Список исп. литературыСкрыть список 1. Бурлаков А.В. К проблеме лечения шизофрении, протекающей с сенестоипохондрическими расстройствами (опыт применения сероквеля). Психиатр. и психофармакотер. 2002; 3: 106–08. 2. Ильина Н.А. Терапия шизофрении и шизоаффективных расстройств: опыт применения кветиапина (Сероквеля). Психиатр. и психофармакотер. 2004; 6 (6): 276–82. 3. Мазо Г.Э. Влияние терапии Сероквелем на депрессивную симптоматику в структуре шизофрении. Психиатр. и психофармакотер. 2003; 5 (6). 4. Максимов В.И. Кветиапин и его место в лечении различных заболеваний среди атипичных антипсихотиков. Совр. тер. псих. расстр. 2009; 2: 24–30. 5. Романов Д.В. Экзистенциальные кризы в дебюте небредовой ипохондрии. Автореф. дис. ... канд. мед. наук. М., 2008. 6. Романов Д.В., Львов А.Н., Функциональный зуд и психические расстройства в дерматологической практике. Тезисы Научно-практической конференции «Психиатрия консультирования и взаимодействия-2009». СПб. 7. Серебрякова Е.В. Небредовая ипохондрия (коэнестезиопатия) при шизотипическом расстройств личности и шизофрении. Автореф. дис. ... канд. мед. наук. М., 2007. 8. Смулевич А.Б., Дубницкая Э.Б. Современный взгляд на проблему ипохондрии в аспекте клиники и терапии. Фарматека. 2006; 7: 71–6. 9. Шинаев Н.Н., Акжигитов Р.Г., Волкова Н.П. Атипичный нейролептик сероквель: возможности применения в клинике пограничных психических расстройств. Психиатр. и психофармакотер. 2004; 6 (3): 122–5. 10. Alexander H, Shah N, Palubin K, Chen S. Prevalence of pruritus in general dermatology clinics. J Am Acad Dermatol 2005; Suppl. 52: P106. 11. Blome С, Schaefer I, Augustin M, StКnder S. National epidemiological study in Germany: Pruritus in a cohort of 11,700 employees. Abstract for 5th International Workshop for the Study of Itch. Acta Derm Venereol 2008; 89: 684–720. 12. Borelli S, Etter H. Antidepressive therapy of neurodermatitis in atopic subjects Dermatologica 1971; 142 (3): 154–60. 13. Brune A, Metze D, Luger TA, Stander S. Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients. Hautarzt 2004; 55 (12): 1130–6. 14. Darsow U, Mautner VF, Bromm B et al. The Eppendorf Pruritus Questionnaire. Hautarzt 1997; 48 (10): 730–3. 15. Davis MP, Frandsen JL, Walsh D et al. Mirtazapine for pruritus. J Pain Symptom Manage 2003; 25 (3): 288–91. 16. Ehrchen J, Stander S. Pregabalin in the treatment of chronic pruritus. J Am Acad Dermatol 2008; 58 (2 Suppl): S36–7. 17. Figueiredo A, Ribeiro CA, Goncalo M et al. Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol 1990; 4 (2): 147–58. 18. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Brit J Dermatol 1998; 139: 846–50. 19. Halvorsen JA, Dalgard F, Thoresen M, Thoresen M et al. Itch and mental distress: a cross-sectional study among late adolescents. Acta Derm Venereol. 2009;89(1):39–44. 20. Harth W, Hermes B, Niemeier V, Gieler U. Clinical pictures and classification of somatoform disorders in dermatology. Eur J Dermatol 2006; 16 (6): 607–14. 21. Huber M, Kirchler E, Karner M, Pycha R. Delusional parasitosis and the dopamine transporter: a new insight of etiology? Med Hypotheses 2007; 68: 1351–8. 22. Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 2005; 53 (5): 916–7. 23. International Forum for the Study of Itch (IFSI) Special Interest Group (IFSI-SIG2): Scoring Itch in Clinical Trials. Protocol of the launch meeting October 26th 2009, Tokyo. 24. Korfitis C, Trafalis DT. Carbamazepine can be effective in alleviating tormenting pruritus in patients with hematologic malignancy. J Pain Symptom Manage 2008; 35 (6): 571–2. 25. Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life. Results of a 1980 National Psoriasis Foundation patient membership survey. Arch Dermatol 2001; 137: 280–4. 26. Lee M, Koo J. Pimozide. The Opiate Antagonist Hypothesis and Use in Delusions of Parasitosis. Dermatol Psychosom 2004; 5: 184–6. 27. Malekzad F, Arbabi M, Mohtasham N et al. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. Eur Acad Dermatol Venereol 2009; 23 (8): 948–50. 28. Matterne U, Strassner T, Apfelbacher CJ et al. Measuring the prevalence of chronic itch in the general population: development and validation of a questionnaire for use in large-scale studies. Acta Derm Venereol 2009; 89 (3): 250–6. 29. Mayo MJ, Handem I, Saldana S et al. Hepatology Sertraline as a first-line treatment for cholestatic pruritus. 2007; 45 (3): 666–74. 30. Mazeh D, Melamed Y, Cholostoy A et al. Itching in the psychiatric ward. Acta Derm Venereol 2008; 88 (2): 128–31. 31. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277–99. 32. Misery L, Alexandre S, Dutray S et al. Functional itch disorder or psychogenic pruritus: suggested diagnosis criteria from the French psychodermatology group. Acta Derm Venereol 2007; 87 (4): 341–4. 33. Modell JG, Boyce S, Taylor E, Katholi C. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study. Psychosom Med 2002; 64 (5): 835–40. 34. Oaklander AL, Bowsher D, Galer B et al. Herpes zoster itch: preliminary epidemiologic data. J Pain 2003; 4: 338–43. 35. Pacan P, Grzesiak M, Reich A, Szepietowski JC. Is pruritus in depression a rare phenomenon? Acta dermato-venereologica 2009; 89 (1): 109–10. 36. Razeghi E, Eskandari D, Ganji MR et al. Gabapentin and uremic pruritus in hemodialysis patients. Ren Fail 2009; 31 (2): 85–90. 37. Reich A, Heisig M, Szepietowski JC. Visual analogue scale as a validated assessment of pruritus intensity. Abstract for 5th International Workshop for the Study of Itch. Acta Derm Venereol 2008; 89: 684–720. 38. Rosenbaum M. Psychosomatic Factors in Pruritus. Psychosom Med 1945; 7: 52–7. 39. Rustin MH. Dermatology. Postgrad Med J 1990;66 (781): 894–905. 40. Savin JA. How should we define itching? JAAD 1998; 39: 268–9. 41. StКnder S et al. Pruritus. 2008. Bremen – London – Boston. P. 93. 42. StКnder S, BЪckenholt B, SchЯrmeyer-Horst F et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009; 89 (1): 45–51. 43. Wolkenstein P, Grob JJ, Bastuji-Garin S et al. SociОtО FranНaise de Dermotologie. French people and skin diseases: results of a survey using a representative sample. Arch Dermatol 2003; 139 (12): 1614–9. 44. Yosipovich G, Goon A, Wee J et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969–73.